In recent years, studies have suggested that GPR115 is abnormally expressed in a variety of malignant tumors (such as breast cancer and glioma), which may promote tumor invasion and drug resistance by activating MAPK/ERK or PI3K/AKT pathways (33–36). Here, ADGRF4 is linked to breast carcinoma.